131 related articles for article (PubMed ID: 9351369)
1. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells.
Kang C; Durlach V; Soulat T; Fournier C; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2036-43. PubMed ID: 9351369
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
3. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody.
Kang C; Dominguez M; Loyau S; Miyata T; Durlach V; Anglés-Cano E
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1232-8. PubMed ID: 12117743
[TBL] [Abstract][Full Text] [Related]
4. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
[TBL] [Abstract][Full Text] [Related]
5. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin.
Hervio L; Girard-Globa A; Durlach V; Anglés-Cano E
Eur J Clin Invest; 1996 May; 26(5):411-7. PubMed ID: 8796369
[TBL] [Abstract][Full Text] [Related]
6. Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis.
Hervio L; Durlach V; Girard-Globa A; Anglés-Cano E
Biochemistry; 1995 Oct; 34(41):13353-8. PubMed ID: 7577920
[TBL] [Abstract][Full Text] [Related]
7. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation.
Bas Leerink C; Duif PF; Gimpel JA; Kortlandt W; Bouma BN; van Rijn HJ
Thromb Haemost; 1992 Aug; 68(2):185-8. PubMed ID: 1412165
[TBL] [Abstract][Full Text] [Related]
8. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.
Martínez C; Rivera J; Loyau S; Corral J; González-Conejero R; Lozano ML; Vicente V; Anglés-Cano E
Thromb Haemost; 2001 Apr; 85(4):686-93. PubMed ID: 11341506
[TBL] [Abstract][Full Text] [Related]
9. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
Rouy D; Koschinsky ML; Fleury V; Chapman J; Anglés-Cano E
Biochemistry; 1992 Jul; 31(27):6333-9. PubMed ID: 1627572
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alphaC-domains.
Tsurupa G; Ho-Tin-Noé B; Anglés-Cano E; Medved L
J Biol Chem; 2003 Sep; 278(39):37154-9. PubMed ID: 12853452
[TBL] [Abstract][Full Text] [Related]
13. Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins.
Trieu VN; Zioncheck TF; Lawn RM; McConathy WJ
J Biol Chem; 1991 Mar; 266(9):5480-5. PubMed ID: 1848551
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
Rouy D; Grailhe P; Nigon F; Chapman J; Anglés-Cano E
Arterioscler Thromb; 1991; 11(3):629-38. PubMed ID: 1827591
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein Lp(a) and atherothrombotic disease.
de la Peña-Díaz A; Izaguirre-Avila R; Anglés-Cano E
Arch Med Res; 2000; 31(4):353-9. PubMed ID: 11068075
[TBL] [Abstract][Full Text] [Related]
16. Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases.
de la Peña-Díaz A; Cardoso-Saldaña G; Zamora-González J; Barinagarrementeria F; Izaguirre R; Loyau S; Anglés-Cano E
Eur J Clin Invest; 2003 Feb; 33(2):99-105. PubMed ID: 12588282
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent.
Knapp JP; Herrmann W
Clin Chem Lab Med; 2004; 42(9):1013-9. PubMed ID: 15497466
[TBL] [Abstract][Full Text] [Related]
18. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin.
Liu J; Harpel PC; Gurewich V
Biochemistry; 1994 Mar; 33(9):2554-60. PubMed ID: 8117716
[TBL] [Abstract][Full Text] [Related]
19. Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes.
Klezovitch O; Edelstein C; Scanu AM
J Clin Invest; 1996 Jul; 98(1):185-91. PubMed ID: 8690792
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis.
Caplice NM; Panetta C; Peterson TE; Kleppe LS; Mueske CS; Kostner GM; Broze GJ; Simari RD
Blood; 2001 Nov; 98(10):2980-7. PubMed ID: 11698280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
